Ankita Patro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ankita Patro has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
David S. Haynes
Department of Otolaryngology‐Head and Neck Surgery Vanderbilt University Nashville Tennessee USA
8 shared publicationsElizabeth L. Perkins
Department of Otolaryngology—Head and Neck Surgery, Vanderbilt University Medical Center
7 shared publicationsNathan R. Lindquist
Department of Otolaryngology–Head and Neck Surgery, Vanderbilt University Medical Center
6 shared publications- David S. Haynes
Vanderbilt University Medical Center
5 shared publications Jourdan T. Holder
Department of Hearing and Speech Sciences, Vanderbilt University Medical Center, Nashville, Tennessee
5 shared publicationsKareem O. Tawfik
Department of Otolaryngology—Head and Neck Surgery, Vanderbilt University Medical Center
5 shared publications
Latest Publications
- Open Access
- 20 July 2026
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 47 (10) , 1239-1245
Does Age Impact Relative Baseline Performance and Improvement on Clinical Speech Recognition Tests in Adult Cochlear Implant Recipients?
Objective: To examine the relative impact of advancing age on clinical speech recognition performance before and after cochlear implantation across tasks varying in auditory and cognitive demands. Study design: Retrospective review of prospectively collected data. Setting: Cochlear implant (CI) center. Patients: Seventy-five CI recipients aged 20 to 88 years (mean=67.6, SD: 15.8). Interventions: Speech recognition before and after CI. Main outcome measures: Pre-CI performance and post-CI improvement on Consonant-Nucleus-Consonant (CNC) word recognition, AzBio sentences in quiet (AzBioQ), and AzBio sentences in noise (AzBioN); multivariate regression models accounting for relevant covariates. Results: Age negatively predicted pre-CI performance on AzBioQ (β=−0.18, P =0.025) and AzBioN (β=−0.17, P =0.024), but not CNC (β=0.00, P =0.988), when controlling for pure-tone average (PTA), duration of deafness (DoD), and sex. Older age predicted less post-CI improvement in AzBioN (β=−0.30, P =0.024), but not CNC (β=−0.24, P =0.054) or AzBioQ (β=−0.18, P =0.171), when controlling for DoD, CI usage, electrode type, and sex. Daily CI usage predicted post-CI improvement in CNC (β=3.80, P =0.001) and AzBioQ (β=3.07, P =0.009), but not AzBioN. Electrode type and sex were not significant predictors of post-CI improvements. Conclusions: Advancing age is associated with poorer pre-CI sentence recognition and smaller gains in post-CI sentence recognition in noise, likely reflecting combined auditory and cognitive changes. These findings highlight the importance of age-informed counseling and expectation-setting for older CI candidates. Level of Evidence: Level IV—Historical cohort or case-controlled studies. Indicate IRB: 240876.
- 20 July 2026
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 47 (10) , 1239-1245
Open AccessDoes Age Impact Relative Baseline Performance and Improvement on Clinical Speech Recognition Tests in Adult Cochlear Implant Recipients?
Objective: To examine the relative impact of advancing age on clinical speech recognition performance before and after cochlear implantation across tasks varying in auditory and cognitive demands. Study design: Retrospective review of prospectively collected data. Setting: Cochlear implant (CI) center. Patients: Seventy-five CI recipients aged 20 to 88 years (mean=67.6, SD: 15.8). Interventions: Speech recognition before and after CI. Main outcome measures: Pre-CI performance and post-CI improvement on Consonant-Nucleus-Consonant (CNC) word recognition, AzBio sentences in quiet (AzBioQ), and AzBio sentences in noise (AzBioN); multivariate regression models accounting for relevant covariates. Results: Age negatively predicted pre-CI performance on AzBioQ (β=−0.18, P =0.025) and AzBioN (β=−0.17, P =0.024), but not CNC (β=0.00, P =0.988), when controlling for pure-tone average (PTA), duration of deafness (DoD), and sex. Older age predicted less post-CI improvement in AzBioN (β=−0.30, P =0.024), but not CNC (β=−0.24, P =0.054) or AzBioQ (β=−0.18, P =0.171), when controlling for DoD, CI usage, electrode type, and sex. Daily CI usage predicted post-CI improvement in CNC (β=3.80, P =0.001) and AzBioQ (β=3.07, P =0.009), but not AzBioN. Electrode type and sex were not significant predictors of post-CI improvements. Conclusions: Advancing age is associated with poorer pre-CI sentence recognition and smaller gains in post-CI sentence recognition in noise, likely reflecting combined auditory and cognitive changes. These findings highlight the importance of age-informed counseling and expectation-setting for older CI candidates. Level of Evidence: Level IV—Historical cohort or case-controlled studies. Indicate IRB: 240876.
- 23 May 2026
- Published by Wiley in The Laryngoscope
- Vol. 136 (S6)
Unique Natural History of Very Small Vestibular Schwannoma Substantiates Size Threshold Surveillance
Objective: Management of vestibular schwannoma (VS) remains controversial. Very small VSs represent a pivotal group: on one hand, they pose the least risk to the patient from the perspective of being small; yet, not recommending treatment may result in missing a critical window for achieving the best outcome. This debate fundamentally hinges on whether treatment improves upon the natural history of the disease. There is an unproven assumption that very small tumors behave similarly to the broader observed population. To address this central question, we conducted a multicenter retrospective review to compare the natural history of tumor growth and hearing for patients with very small VS (1–3 mm) with a referent cohort with larger tumors. Methods: All patients diagnosed with sporadic VS 1–3 mm were reviewed at 3 large skull base referral centers and compared with a referent cohort of patients with tumors > 3 mm. Tumor growth‐free survival rates, treatment‐free survival rates, and rates of maintenance of class A, B, or C hearing were estimated using the Kaplan–Meier method. Results: In total, 123 patients with very small VS and a referent cohort of 326 patients were studied. Seventeen patients with very small VS experienced tumor growth at a median of 3.2 years after diagnosis (IQR 2.6–5.1), demonstrating a median growth rate of 1.0 mm per year (IQR 0.9–1.8). In comparison, 167 of the patients in the referent cohort experienced tumor growth at a median of 1.7 years after diagnosis (IQR 0.8–3.1). Tumor growth‐free survival rates (95% CI, number still at risk) at 5 years after diagnosis for the 2 cohorts were 84% (75–93, 39) and 45% (40–52, 100), respectively ( p < 0.001). Six patients with very small VS underwent treatment after tumor growth at a median of 3.2 years after diagnosis (IQR 3.2–3.8), compared with 138 patients in the referent cohort at a median of 2.2 years after diagnosis (IQR 1.4–3.6). Treatment‐free survival rates (95% CI, number still at risk) at 5 years after diagnosis for the 2 cohorts were 92% (86–98, 55) and 54% (49–61, 125), respectively ( p < 0.001). Among the 105 patients with very small VS and class A, B, or C hearing at diagnosis, 3 progressed to class D. Comparatively, among the 225 patients in the referent cohort with class A, B, or C hearing at diagnosis, 70 progressed to class D at a median of 2.6 years after diagnosis (IQR 1.0–4.8). Rates of maintenance of class A, B, or C hearing (95% CI, number still at risk) at 5 years after diagnosis were 96% (92–100, 28) for patients with very small VS and 65% (57–73, 70) for the referent cohort ( p < 0.001). Conclusions: The natural history of tumor growth and hearing for very small VS diverges favorably from the cumulative natural history data and provides a more appropriate benchmark to compare clinical outcomes of upfront surgery or radiosurgery for this population. At 5 years after diagnosis, 96% of very small VS maintained class A, B, or C hearing and only 8% received treatment for growth within this multicenter cohort. Cumulatively, these data substantiate initial wait‐and‐scan management via size threshold surveillance in this population. Level of Evidence: 3.
- 23 May 2026
- Published by Wiley in The Laryngoscope
- Vol. 136 (S6)
Unique Natural History of Very Small Vestibular Schwannoma Substantiates Size Threshold Surveillance
Objective: Management of vestibular schwannoma (VS) remains controversial. Very small VSs represent a pivotal group: on one hand, they pose the least risk to the patient from the perspective of being small; yet, not recommending treatment may result in missing a critical window for achieving the best outcome. This debate fundamentally hinges on whether treatment improves upon the natural history of the disease. There is an unproven assumption that very small tumors behave similarly to the broader observed population. To address this central question, we conducted a multicenter retrospective review to compare the natural history of tumor growth and hearing for patients with very small VS (1–3 mm) with a referent cohort with larger tumors. Methods: All patients diagnosed with sporadic VS 1–3 mm were reviewed at 3 large skull base referral centers and compared with a referent cohort of patients with tumors > 3 mm. Tumor growth‐free survival rates, treatment‐free survival rates, and rates of maintenance of class A, B, or C hearing were estimated using the Kaplan–Meier method. Results: In total, 123 patients with very small VS and a referent cohort of 326 patients were studied. Seventeen patients with very small VS experienced tumor growth at a median of 3.2 years after diagnosis (IQR 2.6–5.1), demonstrating a median growth rate of 1.0 mm per year (IQR 0.9–1.8). In comparison, 167 of the patients in the referent cohort experienced tumor growth at a median of 1.7 years after diagnosis (IQR 0.8–3.1). Tumor growth‐free survival rates (95% CI, number still at risk) at 5 years after diagnosis for the 2 cohorts were 84% (75–93, 39) and 45% (40–52, 100), respectively ( p < 0.001). Six patients with very small VS underwent treatment after tumor growth at a median of 3.2 years after diagnosis (IQR 3.2–3.8), compared with 138 patients in the referent cohort at a median of 2.2 years after diagnosis (IQR 1.4–3.6). Treatment‐free survival rates (95% CI, number still at risk) at 5 years after diagnosis for the 2 cohorts were 92% (86–98, 55) and 54% (49–61, 125), respectively ( p < 0.001). Among the 105 patients with very small VS and class A, B, or C hearing at diagnosis, 3 progressed to class D. Comparatively, among the 225 patients in the referent cohort with class A, B, or C hearing at diagnosis, 70 progressed to class D at a median of 2.6 years after diagnosis (IQR 1.0–4.8). Rates of maintenance of class A, B, or C hearing (95% CI, number still at risk) at 5 years after diagnosis were 96% (92–100, 28) for patients with very small VS and 65% (57–73, 70) for the referent cohort ( p < 0.001). Conclusions: The natural history of tumor growth and hearing for very small VS diverges favorably from the cumulative natural history data and provides a more appropriate benchmark to compare clinical outcomes of upfront surgery or radiosurgery for this population. At 5 years after diagnosis, 96% of very small VS maintained class A, B, or C hearing and only 8% received treatment for growth within this multicenter cohort. Cumulatively, these data substantiate initial wait‐and‐scan management via size threshold surveillance in this population. Level of Evidence: 3.
- Open Access
- 23 October 2025
- Published by SAGE Publications in Annals of Otology, Rhinology & Laryngology
- Vol. 135 (2) , 146-153
Multiple Drug-Induced Sleep Endoscopy in Pediatric Obstructive Sleep Apnea: Obstruction Patterns and Outcomes
Objectives: Residual obstructive sleep apnea (OSA) following adenotonsillectomy (AT) is common in children with obesity. Drug-induced sleep endoscopy (DISE) identifies upper airway obstruction and guides surgery. A gap remains in evaluating multiple DISE-directed treatments. This study evaluates multiple DISE-directed procedure outcomes, obstruction patterns, and BMI in pediatric patients. Methods: This single-institution retrospective cohort study included pediatric patients who underwent DISE-directed interventions from 2009 to 2020. Variables included patient characteristics, DISE timing, obstruction patterns, obstructive apnea-hypopnea index (OAHI), and OSA-18 quality-of-life (QOL). Chi-square tests compared patient demographics and comorbidities between single and multiple DISE groups. Unpaired t -tests compared age, OAHI, and OSA-18 scores between single and multiple DISE groups as well as multiple-DISE outcomes for high versus normal BMI groups. Results: Of 122 children who underwent DISE, 27 (22%) had multiple DISE-directed procedures. Average age at first DISE for single and multiple DISE patients was 7.25 (SD = 3.93) and 4.99 (SD = 3.63) years, respectively ( P < .01). Common obstructions at second DISE involved the epiglottis (N = 20, 74%), adenoid (N = 18, 67%), and inferior turbinates (N = 15, 56%). Multilevel obstruction was identified in 96% (N = 26) of second and 80% (N = 4) of third DISEs. Children with high BMI (versus normal BMI) exhibited shorter intervals between DISEs. Patients who underwent single DISE exhibited significant OAHI improvement (mean 8.48 vs 3.91, P < .05), but this was not significant for multiple DISEs. The OSA-18 score improved significantly in patients with single DISE (mean summed score 61.3 vs 44.6, P < .05). Conclusions: Pediatric OSA involves persistent, multilevel obstruction, especially in younger patients with elevated BMI undergoing multiple DISE-directed procedures. These findings support anatomy-guided, patient-specific surgical planning for high-risk groups. While a single DISE-directed intervention can significantly improve OAHI and QOL, repeated procedures may yield diminishing returns, underscoring the need to consider their timing and utility. Early multidisciplinary evaluation and long-term follow-up are essential for managing persistent OSA.
- 23 October 2025
- Published by SAGE Publications in Annals of Otology, Rhinology & Laryngology
- Vol. 135 (2) , 146-153
Open AccessMultiple Drug-Induced Sleep Endoscopy in Pediatric Obstructive Sleep Apnea: Obstruction Patterns and Outcomes
Objectives: Residual obstructive sleep apnea (OSA) following adenotonsillectomy (AT) is common in children with obesity. Drug-induced sleep endoscopy (DISE) identifies upper airway obstruction and guides surgery. A gap remains in evaluating multiple DISE-directed treatments. This study evaluates multiple DISE-directed procedure outcomes, obstruction patterns, and BMI in pediatric patients. Methods: This single-institution retrospective cohort study included pediatric patients who underwent DISE-directed interventions from 2009 to 2020. Variables included patient characteristics, DISE timing, obstruction patterns, obstructive apnea-hypopnea index (OAHI), and OSA-18 quality-of-life (QOL). Chi-square tests compared patient demographics and comorbidities between single and multiple DISE groups. Unpaired t -tests compared age, OAHI, and OSA-18 scores between single and multiple DISE groups as well as multiple-DISE outcomes for high versus normal BMI groups. Results: Of 122 children who underwent DISE, 27 (22%) had multiple DISE-directed procedures. Average age at first DISE for single and multiple DISE patients was 7.25 (SD = 3.93) and 4.99 (SD = 3.63) years, respectively ( P < .01). Common obstructions at second DISE involved the epiglottis (N = 20, 74%), adenoid (N = 18, 67%), and inferior turbinates (N = 15, 56%). Multilevel obstruction was identified in 96% (N = 26) of second and 80% (N = 4) of third DISEs. Children with high BMI (versus normal BMI) exhibited shorter intervals between DISEs. Patients who underwent single DISE exhibited significant OAHI improvement (mean 8.48 vs 3.91, P < .05), but this was not significant for multiple DISEs. The OSA-18 score improved significantly in patients with single DISE (mean summed score 61.3 vs 44.6, P < .05). Conclusions: Pediatric OSA involves persistent, multilevel obstruction, especially in younger patients with elevated BMI undergoing multiple DISE-directed procedures. These findings support anatomy-guided, patient-specific surgical planning for high-risk groups. While a single DISE-directed intervention can significantly improve OAHI and QOL, repeated procedures may yield diminishing returns, underscoring the need to consider their timing and utility. Early multidisciplinary evaluation and long-term follow-up are essential for managing persistent OSA.
- 21 November 2024
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 46 (1) , 54-59
Patient Preferences in Cochlear Implant Manufacturer Selection
Objective: To assess the factors that drive a patient’s selection of cochlear implant (CI) manufacturer. Study Design: Prospective survey study. Setting: Tertiary referral center. Patients: One hundred twenty-eight adult patients undergoing primary CI. Interventions: Survey administered in the preoperative area. Main Outcome Measures: Sources of information regarding CI manufacturer offerings, factors that were most important in deciding on a manufacturer, and manufacturer ultimately selected. Results: One hundred twenty-eight patients were included (average age, 63.7 years; 97% White). The most cited source of information that patients used to choose a device was his/her audiologist (80.5% of patients). When asked his/her number 1 reason for choosing their CI manufacturer, the most commonly cited reason was technology (e.g., battery life, device pairing), regardless of manufacturer. When asked about specific technology offerings, hearing aid pairing was rated as the most important. The numbers 2 and 3 reasons for choosing a manufacturer were cosmetics/structure of the wearable portion of the device and audiologist recommendation of that manufacturer, respectively. The relative weight given to each of the top 3 reasons differed significantly across the three manufacturers (p = 0.017). Conclusions: Audiologists are by far the leading source of information used by patients choosing a CI manufacturer. Patients prioritize technology most when choosing an implant manufacturer, but audiologist recommendation and the cosmetics and structure of the wearable device are also important. CI manufacturers should be mindful of patient priorities when designing and marketing their devices.
- 21 November 2024
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 46 (1) , 54-59
Patient Preferences in Cochlear Implant Manufacturer Selection
Objective: To assess the factors that drive a patient’s selection of cochlear implant (CI) manufacturer. Study Design: Prospective survey study. Setting: Tertiary referral center. Patients: One hundred twenty-eight adult patients undergoing primary CI. Interventions: Survey administered in the preoperative area. Main Outcome Measures: Sources of information regarding CI manufacturer offerings, factors that were most important in deciding on a manufacturer, and manufacturer ultimately selected. Results: One hundred twenty-eight patients were included (average age, 63.7 years; 97% White). The most cited source of information that patients used to choose a device was his/her audiologist (80.5% of patients). When asked his/her number 1 reason for choosing their CI manufacturer, the most commonly cited reason was technology (e.g., battery life, device pairing), regardless of manufacturer. When asked about specific technology offerings, hearing aid pairing was rated as the most important. The numbers 2 and 3 reasons for choosing a manufacturer were cosmetics/structure of the wearable portion of the device and audiologist recommendation of that manufacturer, respectively. The relative weight given to each of the top 3 reasons differed significantly across the three manufacturers (p = 0.017). Conclusions: Audiologists are by far the leading source of information used by patients choosing a CI manufacturer. Patients prioritize technology most when choosing an implant manufacturer, but audiologist recommendation and the cosmetics and structure of the wearable device are also important. CI manufacturers should be mindful of patient priorities when designing and marketing their devices.
- 1 October 2024
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 45 (9) , e639-e643
Investigating the Minimal Clinically Important Difference for AzBio and CNC Speech Recognition Scores
Objective: To assess the minimal clinically important difference (MCID) values for cochlear implant-related speech recognition scores, which have not been previously reported. Study Design: Retrospective cohort. Setting: Tertiary referral center. Patients: Eight hundred sixty-three adult patients who underwent cochlear implantation between 2009 and 2022. Main Outcome Measures: MCID values for consonant-nucleus-consonant (CNC) word scores and AzBio sentences in quiet and noise scores using distribution-based methods (half-standard deviation, standard error of measurement, Cohen's d, and minimum detectable change). Results: In this cohort, the mean preoperative CNC word score was 13.9% (SD, 15.6). The mean preoperative AzBio sentences in quiet score was 19.1% (SD, 22.1), and the mean preoperative AzBio sentences in noise score was 13.0% (SD, 12.0). The average MCID values of several distribution-based methods for CNC, AzBio in quiet, and AzBio in noise were 7.4%, 9.0%, and 4.9%, respectively. Anchor-based approaches with the Speech, Spatial, and Qualities of hearing patient-reported measure did not have strong classification accuracy across CNC or AzBio in quiet and noise scores (ROC areas under-the-curve ≤0.69), highlighting weak associations between improvements in speech recognition scores and subjective hearing-related abilities. Conclusions: Our estimation of MCID values for CNC and AzBio in quiet and noise allows for enhanced patient counseling and clinical interpretation of past, current, and future research studies assessing cochlear implant outcomes.
- 1 October 2024
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 45 (9) , e639-e643
Investigating the Minimal Clinically Important Difference for AzBio and CNC Speech Recognition Scores
Objective: To assess the minimal clinically important difference (MCID) values for cochlear implant-related speech recognition scores, which have not been previously reported. Study Design: Retrospective cohort. Setting: Tertiary referral center. Patients: Eight hundred sixty-three adult patients who underwent cochlear implantation between 2009 and 2022. Main Outcome Measures: MCID values for consonant-nucleus-consonant (CNC) word scores and AzBio sentences in quiet and noise scores using distribution-based methods (half-standard deviation, standard error of measurement, Cohen's d, and minimum detectable change). Results: In this cohort, the mean preoperative CNC word score was 13.9% (SD, 15.6). The mean preoperative AzBio sentences in quiet score was 19.1% (SD, 22.1), and the mean preoperative AzBio sentences in noise score was 13.0% (SD, 12.0). The average MCID values of several distribution-based methods for CNC, AzBio in quiet, and AzBio in noise were 7.4%, 9.0%, and 4.9%, respectively. Anchor-based approaches with the Speech, Spatial, and Qualities of hearing patient-reported measure did not have strong classification accuracy across CNC or AzBio in quiet and noise scores (ROC areas under-the-curve ≤0.69), highlighting weak associations between improvements in speech recognition scores and subjective hearing-related abilities. Conclusions: Our estimation of MCID values for CNC and AzBio in quiet and noise allows for enhanced patient counseling and clinical interpretation of past, current, and future research studies assessing cochlear implant outcomes.
- Open Access
- 31 May 2024
- Published by Springer Nature in Current Otorhinolaryngology Reports
- Vol. 12 (3) , 45-49
Machine Learning to Predict Adult Cochlear Implant Candidacy
Purpose of Review: The purpose of this review is to summarize candidacy criteria and commonly used referral guidelines for adult cochlear implant (CI) patients. This review describes how machine learning can be used to predict CI candidacy and the potential impact of an automated referral guideline. Recent Findings: Less than 2% of eligible adults are receiving CIs under traditional and expanded candidacy criteria. Lack of understanding of referral criteria, both among providers and patients, significantly contributes to the underutilization of CIs. Recently, a novel machine learning-based CI referral algorithm has been developed that shows high sensitivity, specificity, and accuracy in predicting CI candidacy among adults. Summary: An automated, machine learning-based referral guideline can mitigate the lack of clarity regarding when to refer a patient and help bridge the large gap in CI care delivery that currently exists. Future research needs to externally validate such an algorithm and evaluate its uptake in routine clinical settings.
- 31 May 2024
- Published by Springer Nature in Current Otorhinolaryngology Reports
- Vol. 12 (3) , 45-49
Open AccessMachine Learning to Predict Adult Cochlear Implant Candidacy
Purpose of Review: The purpose of this review is to summarize candidacy criteria and commonly used referral guidelines for adult cochlear implant (CI) patients. This review describes how machine learning can be used to predict CI candidacy and the potential impact of an automated referral guideline. Recent Findings: Less than 2% of eligible adults are receiving CIs under traditional and expanded candidacy criteria. Lack of understanding of referral criteria, both among providers and patients, significantly contributes to the underutilization of CIs. Recently, a novel machine learning-based CI referral algorithm has been developed that shows high sensitivity, specificity, and accuracy in predicting CI candidacy among adults. Summary: An automated, machine learning-based referral guideline can mitigate the lack of clarity regarding when to refer a patient and help bridge the large gap in CI care delivery that currently exists. Future research needs to externally validate such an algorithm and evaluate its uptake in routine clinical settings.
- Open Access
Barriers to Cochlear Implant Uptake in Adults: A Scoping Review
Introduction Cochlear Implants (CIs) provide access to sound and help mitigate the negative effects of hearing loss. As a field, we are successfully implanting more adults with greater amounts of residual hearing than ever before. Despite this, utilization remains low, which is thought to arise from barriers that are both intrinsic and extrinsic. A considerable body of literature has been published in the last five years on barriers to adult CI uptake, and understanding these barriers is critical to improving access and utilization. This scoping review aims to summarize the existing literature and provide a guide to understanding barriers to adult CI uptake. Methods Inclusion criteria were limited to peer-reviewed articles involving adults, written in English, and accessible with a university library subscription. A cutoff of 20 years was used to limit the search. Barriers uncovered in this review were categorized into an ecological framework. Results The initial search revealed 2,315 items after duplicates were removed. One hundred thirty-one articles were reviewed under full-text, and 68 articles met inclusion criteria. Discussion Race, ethnicity, and reimbursement are policy and structural barriers. Public awareness and education are societal barriers. Referral and geographical challenges are forms of organizational barriers. Living context and professional support are interpersonal barriers. At the individual level sound quality, uncertainty of outcome, surgery, loss of residual hearing, and irreversibility are all barriers to CI uptake. By organizing barriers into an ecological framework, targeted interventions can be used to overcome such barriers.
Open AccessBarriers to Cochlear Implant Uptake in Adults: A Scoping Review
Introduction Cochlear Implants (CIs) provide access to sound and help mitigate the negative effects of hearing loss. As a field, we are successfully implanting more adults with greater amounts of residual hearing than ever before. Despite this, utilization remains low, which is thought to arise from barriers that are both intrinsic and extrinsic. A considerable body of literature has been published in the last five years on barriers to adult CI uptake, and understanding these barriers is critical to improving access and utilization. This scoping review aims to summarize the existing literature and provide a guide to understanding barriers to adult CI uptake. Methods Inclusion criteria were limited to peer-reviewed articles involving adults, written in English, and accessible with a university library subscription. A cutoff of 20 years was used to limit the search. Barriers uncovered in this review were categorized into an ecological framework. Results The initial search revealed 2,315 items after duplicates were removed. One hundred thirty-one articles were reviewed under full-text, and 68 articles met inclusion criteria. Discussion Race, ethnicity, and reimbursement are policy and structural barriers. Public awareness and education are societal barriers. Referral and geographical challenges are forms of organizational barriers. Living context and professional support are interpersonal barriers. At the individual level sound quality, uncertainty of outcome, surgery, loss of residual hearing, and irreversibility are all barriers to CI uptake. By organizing barriers into an ecological framework, targeted interventions can be used to overcome such barriers.
- 22 November 2023
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 45 (1) , 52-57
Comparison of Speech Recognition and Hearing Preservation Outcomes Between the Mid-Scala and Lateral Wall Electrode Arrays
Objective: To assess speech recognition and hearing preservation (HP) outcomes with the Advanced Bionics Mid-Scala and SlimJ electrodes.Study Design: Retrospective cohort.Setting: Tertiary referral center.Patients: A total of 237 adult patients implanted between 2013 and 2020 (Mid-Scala, n = 136; SlimJ, n = 101).Main Outcome Measures: Consonant-nucleus-consonant (CNC) and AzBio (Arizona Biomedical) scores at 6 and 12 months; postoperative HP, defined as low-frequency pure-tone average ≤ 80 dB HL; scalar position.Results: Mean CNC scores did not significantly differ between Mid-Scala and SlimJ recipients at 6 (45.8% versus 46.0%,p= 0.962) and 12 (51.9% versus 48.8%,p= 0.363) months. Similarly, mean AzBio in quiet scores were equivalent for both groups at 6 (55.1% versus 59.2%,p= 0.334) and 12 (60.6% versus 62.3%,p= 0.684) months. HP rates were significantly higher with the SlimJ (48.4%) than the Mid-Scala (30.8%;p= 0.033). Scalar translocations were 34.8 and 16.1% for the Mid-Scala and SlimJ groups, respectively (p= 0.019). Ears with postoperative HP had significantly fewer scalar translocations (16.7% versus 37.2%,p= 0.048), and postoperative HP was associated with higher AzBio in noise scores at the most recent follow-up interval (38.7% versus 25.1%,p= 0.042). CNC, AzBio in quiet and noise, low-frequency pure-tone average shifts, and PTA at 6 and 12 months were not significantly different between patients with scala tympani insertions of the SlimJ versus the Mid-Scala (p> 0.05).Conclusions: Compared with the Mid-Scala, the lateral wall electrode has superior HP rates and fewer scalar translocations, whereas speech recognition scores are equivalent between both electrode arrays. These findings can help providers with electrode selection and patient counseling.
- 22 November 2023
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 45 (1) , 52-57
Comparison of Speech Recognition and Hearing Preservation Outcomes Between the Mid-Scala and Lateral Wall Electrode Arrays
Objective: To assess speech recognition and hearing preservation (HP) outcomes with the Advanced Bionics Mid-Scala and SlimJ electrodes.Study Design: Retrospective cohort.Setting: Tertiary referral center.Patients: A total of 237 adult patients implanted between 2013 and 2020 (Mid-Scala, n = 136; SlimJ, n = 101).Main Outcome Measures: Consonant-nucleus-consonant (CNC) and AzBio (Arizona Biomedical) scores at 6 and 12 months; postoperative HP, defined as low-frequency pure-tone average ≤ 80 dB HL; scalar position.Results: Mean CNC scores did not significantly differ between Mid-Scala and SlimJ recipients at 6 (45.8% versus 46.0%,p= 0.962) and 12 (51.9% versus 48.8%,p= 0.363) months. Similarly, mean AzBio in quiet scores were equivalent for both groups at 6 (55.1% versus 59.2%,p= 0.334) and 12 (60.6% versus 62.3%,p= 0.684) months. HP rates were significantly higher with the SlimJ (48.4%) than the Mid-Scala (30.8%;p= 0.033). Scalar translocations were 34.8 and 16.1% for the Mid-Scala and SlimJ groups, respectively (p= 0.019). Ears with postoperative HP had significantly fewer scalar translocations (16.7% versus 37.2%,p= 0.048), and postoperative HP was associated with higher AzBio in noise scores at the most recent follow-up interval (38.7% versus 25.1%,p= 0.042). CNC, AzBio in quiet and noise, low-frequency pure-tone average shifts, and PTA at 6 and 12 months were not significantly different between patients with scala tympani insertions of the SlimJ versus the Mid-Scala (p> 0.05).Conclusions: Compared with the Mid-Scala, the lateral wall electrode has superior HP rates and fewer scalar translocations, whereas speech recognition scores are equivalent between both electrode arrays. These findings can help providers with electrode selection and patient counseling.
- 29 June 2023
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 44 (7) , e486-e491
Machine Learning Approach for Screening Cochlear Implant Candidates: Comparing With the 60/60 Guideline
Objective: To develop a machine learning–based referral guideline for patients undergoing cochlear implant candidacy evaluation (CICE) and to compare with the widely used 60/60 guideline. Study Design: Retrospective cohort. Setting: Tertiary referral center. Patients: 772 adults undergoing CICE from 2015 to 2020. Interventions: Variables included demographics, unaided thresholds, and word recognition score. A random forest classification model was trained on patients undergoing CICE, and bootstrap cross-validation was used to assess the modeling approach's performance. Main Outcome Measures: The machine learning–based referral tool was evaluated against the 60/60 guideline based on ability to identify CI candidates under traditional and expanded criteria. Results: Of 587 patients with complete data, 563 (96%) met candidacy at our center, and the 60/60 guideline identified 512 (87%) patients. In the random forest model, word recognition score; thresholds at 3000, 2000, and 125; and age at CICE had the largest impact on candidacy (mean decrease in Gini coefficient, 2.83, 1.60, 1.20, 1.17, and 1.16, respectively). The 60/60 guideline had a sensitivity of 0.91, a specificity of 0.42, and an accuracy of 0.89 (95% confidence interval, 0.86–0.91). The random forest model obtained higher sensitivity (0.96), specificity (1.00), and accuracy (0.96; 95% confidence interval, 0.95–0.98). Across 1,000 bootstrapped iterations, the model yielded a median sensitivity of 0.92 (interquartile range [IQR], 0.85–0.98), specificity of 1.00 (IQR, 0.88–1.00), accuracy of 0.93 (IQR, 0.85–0.97), and area under the curve of 0.96 (IQR, 0.93–0.98). Conclusions: A novel machine learning–based screening model is highly sensitive, specific, and accurate in predicting CI candidacy. Bootstrapping confirmed that this approach is potentially generalizable with consistent results.
- 29 June 2023
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 44 (7) , e486-e491
Machine Learning Approach for Screening Cochlear Implant Candidates: Comparing With the 60/60 Guideline
Objective: To develop a machine learning–based referral guideline for patients undergoing cochlear implant candidacy evaluation (CICE) and to compare with the widely used 60/60 guideline. Study Design: Retrospective cohort. Setting: Tertiary referral center. Patients: 772 adults undergoing CICE from 2015 to 2020. Interventions: Variables included demographics, unaided thresholds, and word recognition score. A random forest classification model was trained on patients undergoing CICE, and bootstrap cross-validation was used to assess the modeling approach's performance. Main Outcome Measures: The machine learning–based referral tool was evaluated against the 60/60 guideline based on ability to identify CI candidates under traditional and expanded criteria. Results: Of 587 patients with complete data, 563 (96%) met candidacy at our center, and the 60/60 guideline identified 512 (87%) patients. In the random forest model, word recognition score; thresholds at 3000, 2000, and 125; and age at CICE had the largest impact on candidacy (mean decrease in Gini coefficient, 2.83, 1.60, 1.20, 1.17, and 1.16, respectively). The 60/60 guideline had a sensitivity of 0.91, a specificity of 0.42, and an accuracy of 0.89 (95% confidence interval, 0.86–0.91). The random forest model obtained higher sensitivity (0.96), specificity (1.00), and accuracy (0.96; 95% confidence interval, 0.95–0.98). Across 1,000 bootstrapped iterations, the model yielded a median sensitivity of 0.92 (interquartile range [IQR], 0.85–0.98), specificity of 1.00 (IQR, 0.88–1.00), accuracy of 0.93 (IQR, 0.85–0.97), and area under the curve of 0.96 (IQR, 0.93–0.98). Conclusions: A novel machine learning–based screening model is highly sensitive, specific, and accurate in predicting CI candidacy. Bootstrapping confirmed that this approach is potentially generalizable with consistent results.
- 26 May 2023
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 169 (6) , 1615-1623
Cochlear Implantation in Very Young Children With Single‐Sided Deafness
Objective: Cochlear implants (CIs) for single‐sided deafness (SSD) have only been approved for patients 5 years and older despite data supporting that younger children can also benefit from implantation. This study describes our institution's experience with CI for SSD in children 5 years and younger.Study Design: Case series with chart review.Setting: Tertiary referral center.Methods: A case series with chart review identified 19 patients up to age 5 years who underwent CI for SSD between 2014 and 2022. Baseline characteristics, perioperative complications, device usage, and speech outcomes were collected.Results: The median age at CI was 2.8 (range, 1.0‐5.4) years, with 15 (79%) patients being below age 5 at implantation. Etiologies of hearing loss were idiopathic (n = 8), cytomegalovirus (n = 4), enlarged vestibular aqueduct (n = 3), hypoplastic cochlear nerve (n = 3), and meningitis (n = 1). The median preoperative pure‐tone average was 90 (range, 75‐120) and 20 (range, 5‐35) dB eHL in the poor and better hearing ears, respectively. No patients had postoperative complications. Twelve patients achieved consistent device use (average, 9 h/d). Three of the seven who were not consistent users had hypoplastic cochlear nerves and/or developmental delays. The three patients with available preoperative and postoperative speech testing showed significant benefits, and five patients with available postoperative testing demonstrated speech recognition in the implanted ear when isolated from the better ear.Conclusion: CI can safely be performed in younger children with SSD. Patients and families accept early implantation, as evidenced by consistent device use, and derive notable benefits in speech recognition. Candidacy can be broadened to include SSD patients under age five years, particularly individuals without hypoplastic cochlear nerves or developmental delay.
- 26 May 2023
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 169 (6) , 1615-1623
Cochlear Implantation in Very Young Children With Single‐Sided Deafness
Objective: Cochlear implants (CIs) for single‐sided deafness (SSD) have only been approved for patients 5 years and older despite data supporting that younger children can also benefit from implantation. This study describes our institution's experience with CI for SSD in children 5 years and younger.Study Design: Case series with chart review.Setting: Tertiary referral center.Methods: A case series with chart review identified 19 patients up to age 5 years who underwent CI for SSD between 2014 and 2022. Baseline characteristics, perioperative complications, device usage, and speech outcomes were collected.Results: The median age at CI was 2.8 (range, 1.0‐5.4) years, with 15 (79%) patients being below age 5 at implantation. Etiologies of hearing loss were idiopathic (n = 8), cytomegalovirus (n = 4), enlarged vestibular aqueduct (n = 3), hypoplastic cochlear nerve (n = 3), and meningitis (n = 1). The median preoperative pure‐tone average was 90 (range, 75‐120) and 20 (range, 5‐35) dB eHL in the poor and better hearing ears, respectively. No patients had postoperative complications. Twelve patients achieved consistent device use (average, 9 h/d). Three of the seven who were not consistent users had hypoplastic cochlear nerves and/or developmental delays. The three patients with available preoperative and postoperative speech testing showed significant benefits, and five patients with available postoperative testing demonstrated speech recognition in the implanted ear when isolated from the better ear.Conclusion: CI can safely be performed in younger children with SSD. Patients and families accept early implantation, as evidenced by consistent device use, and derive notable benefits in speech recognition. Candidacy can be broadened to include SSD patients under age five years, particularly individuals without hypoplastic cochlear nerves or developmental delay.